StreetInsider.com News Articles

MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA

Wed, 13 May 2026 07:30:00 -0400

Q1 2026 Positive Adjusted EBITDA(1)
Net Revenue of $9M with strong gross margins of 37%
OPEX decreased 28% in Q1 2026 versus Q4 2025
Company is virtually debt free, with a Q1 ending cash balance of $9.9 million and outright ownership of two licensed production facilities
Management to Host Conference Call / Webcast on May 13th, 2026, at 10:00 am ET

TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, today announced

MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA

Wed, 13 May 2026 07:30:00 -0400

Q1 2026 Positive Adjusted EBITDA(1)
Net Revenue of $9M with strong gross margins of 37%
OPEX decreased 28% in Q1 2026 versus Q4 2025
Company is virtually debt free, with a Q1 ending cash balance of $9.9 million and outright ownership of two licensed production facilities
Management to Host Conference Call / Webcast on May 13th, 2026, at 10:00 am ET

MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA

Wed, 13 May 2026 07:30:00 -0400

Q1 2026 Positive Adjusted EBITDA(1)
Net Revenue of $9M with strong gross margins of 37%
OPEX decreased 28% in Q1 2026 versus Q4 2025
Company is virtually debt free, with a Q1 ending cash balance of $9.9 million and outright ownership of two licensed production facilities
Management to Host Conference Call / Webcast on May 13th, 2026, at 10:00 am ET

MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA

Wed, 13 May 2026 07:30:00 -0400

Q1 2026 Positive Adjusted EBITDA(1)
Net Revenue of $9M with strong gross margins of 37%
OPEX decreased 28% in Q1 2026 versus Q4 2025
Company is virtually debt free, with a Q1 ending cash balance of $9.9 million and outright ownership of two licensed production facilities
Management to Host Conference Call / Webcast on May 13th, 2026, at 10:00 am ET

MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA

Wed, 13 May 2026 07:30:00 -0400

Q1 2026 Positive Adjusted EBITDA(1)
Net Revenue of $9M with strong gross margins of 37%
OPEX decreased 28% in Q1 2026 versus Q4 2025
Company is virtually debt free, with a Q1 ending cash balance of $9.9 million and outright ownership of two licensed production facilities
Management to Host Conference Call / Webcast on May 13th, 2026, at 10:00 am ET

MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA

Wed, 13 May 2026 07:30:00 -0400

Q1 2026 Positive Adjusted EBITDA(1)
Net Revenue of $9M with strong gross margins of 37%
OPEX decreased 28% in Q1 2026 versus Q4 2025
Company is virtually debt free, with a Q1 ending cash balance of $9.9 million and outright ownership of two licensed production facilities
Management to Host Conference Call / Webcast on May 13th, 2026, at 10:00 am ET

MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA

Wed, 13 May 2026 07:30:00 -0400

Q1 2026 Positive Adjusted EBITDA(1)
Net Revenue of $9M with strong gross margins of 37%
OPEX decreased 28% in Q1 2026 versus Q4 2025
Company is virtually debt free, with a Q1 ending cash balance of $9.9 million and outright ownership of two licensed production facilities
Management to Host Conference Call / Webcast on May 13th, 2026, at 10:00 am ET

MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA

Wed, 13 May 2026 07:30:00 -0400

Q1 2026 Positive Adjusted EBITDA(1)
Net Revenue of $9M with strong gross margins of 37%
OPEX decreased 28% in Q1 2026 versus Q4 2025
Company is virtually debt free, with a Q1 ending cash balance of $9.9 million and outright ownership of two licensed production facilities
Management to Host Conference Call / Webcast on May 13th, 2026, at 10:00 am ET

MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA

Wed, 13 May 2026 07:30:00 -0400

Q1 2026 Positive Adjusted EBITDA(1)
Net Revenue of $9M with strong gross margins of 37%
OPEX decreased 28% in Q1 2026 versus Q4 2025
Company is virtually debt free, with a Q1 ending cash balance of $9.9 million and outright ownership of two licensed production facilities
Management to Host Conference Call / Webcast on May 13th, 2026, at 10:00 am ET

MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA

Wed, 13 May 2026 07:30:00 -0400

Q1 2026 Positive Adjusted EBITDA(1)
Net Revenue of $9M with strong gross margins of 37%
OPEX decreased 28% in Q1 2026 versus Q4 2025
Company is virtually debt free, with a Q1 ending cash balance of $9.9 million and outright ownership of two licensed production facilities
Management to Host Conference Call / Webcast on May 13th, 2026, at 10:00 am ET

MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA

Wed, 13 May 2026 07:30:00 -0400

Q1 2026 Positive Adjusted EBITDA(1)
Net Revenue of $9M with strong gross margins of 37%
OPEX decreased 28% in Q1 2026 versus Q4 2025
Company is virtually debt free, with a Q1 ending cash balance of $9.9 million and outright ownership of two licensed production facilities
Management to Host Conference Call / Webcast on May 13th, 2026, at 10:00 am ET

MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA

Wed, 13 May 2026 07:30:00 -0400

Q1 2026 Positive Adjusted EBITDA(1)
Net Revenue of $9M with strong gross margins of 37%
OPEX decreased 28% in Q1 2026 versus Q4 2025
Company is virtually debt free, with a Q1 ending cash balance of $9.9 million and outright ownership of two licensed production facilities
Management to Host Conference Call / Webcast on May 13th, 2026, at 10:00 am ET

MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA

Wed, 13 May 2026 07:30:00 -0400

Q1 2026 Positive Adjusted EBITDA(1)
Net Revenue of $9M with strong gross margins of 37%
OPEX decreased 28% in Q1 2026 versus Q4 2025
Company is virtually debt free, with a Q1 ending cash balance of $9.9 million and outright ownership of two licensed production facilities
Management to Host Conference Call / Webcast on May 13th, 2026, at 10:00 am ET

MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA

Wed, 13 May 2026 07:30:00 -0400

Q1 2026 Positive Adjusted EBITDA(1)
Net Revenue of $9M with strong gross margins of 37%
OPEX decreased 28% in Q1 2026 versus Q4 2025
Company is virtually debt free, with a Q1 ending cash balance of $9.9 million and outright ownership of two licensed production facilities
Management to Host Conference Call / Webcast on May 13th, 2026, at 10:00 am ET

MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA

Wed, 13 May 2026 07:30:00 -0400

Q1 2026 Positive Adjusted EBITDA(1)
Net Revenue of $9M with strong gross margins of 37%
OPEX decreased 28% in Q1 2026 versus Q4 2025
Company is virtually debt free, with a Q1 ending cash balance of $9.9 million and outright ownership of two licensed production facilities
Management to Host Conference Call / Webcast on May 13th, 2026, at 10:00 am ET

MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA

Wed, 13 May 2026 07:30:00 -0400

Q1 2026 Positive Adjusted EBITDA(1)
Net Revenue of $9M with strong gross margins of 37%
OPEX decreased 28% in Q1 2026 versus Q4 2025
Company is virtually debt free, with a Q1 ending cash balance of $9.9 million and outright ownership of two licensed production facilities
Management to Host Conference Call / Webcast on May 13th, 2026, at 10:00 am ET

MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA

Wed, 13 May 2026 07:30:00 -0400

Q1 2026 Positive Adjusted EBITDA(1)
Net Revenue of $9M with strong gross margins of 37%
OPEX decreased 28% in Q1 2026 versus Q4 2025
Company is virtually debt free, with a Q1 ending cash balance of $9.9 million and outright ownership of two licensed production facilities
Management to Host Conference Call / Webcast on May 13th, 2026, at 10:00 am ET

MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA

Wed, 13 May 2026 07:30:00 -0400

Q1 2026 Positive Adjusted EBITDA(1)
Net Revenue of $9M with strong gross margins of 37%
OPEX decreased 28% in Q1 2026 versus Q4 2025
Company is virtually debt free, with a Q1 ending cash balance of $9.9 million and outright ownership of two licensed production facilities
Management to Host Conference Call / Webcast on May 13th, 2026, at 10:00 am ET

MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA

Wed, 13 May 2026 07:30:00 -0400

Q1 2026 Positive Adjusted EBITDA(1)
Net Revenue of $9M with strong gross margins of 37%
OPEX decreased 28% in Q1 2026 versus Q4 2025
Company is virtually debt free, with a Q1 ending cash balance of $9.9 million and outright ownership of two licensed production facilities
Management to Host Conference Call / Webcast on May 13th, 2026, at 10:00 am ET

MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA

Wed, 13 May 2026 07:30:00 -0400

Q1 2026 Positive Adjusted EBITDA(1)
Net Revenue of $9M with strong gross margins of 37%
OPEX decreased 28% in Q1 2026 versus Q4 2025
Company is virtually debt free, with a Q1 ending cash balance of $9.9 million and outright ownership of two licensed production facilities
Management to Host Conference Call / Webcast on May 13th, 2026, at 10:00 am ET

MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA

Wed, 13 May 2026 07:30:00 -0400

Q1 2026 Positive Adjusted EBITDA(1)
Net Revenue of $9M with strong gross margins of 37%
OPEX decreased 28% in Q1 2026 versus Q4 2025
Company is virtually debt free, with a Q1 ending cash balance of $9.9 million and outright ownership of two licensed production facilities
Management to Host Conference Call / Webcast on May 13th, 2026, at 10:00 am ET

MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA

Wed, 13 May 2026 07:30:00 -0400

Q1 2026 Positive Adjusted EBITDA(1)
Net Revenue of $9M with strong gross margins of 37%
OPEX decreased 28% in Q1 2026 versus Q4 2025
Company is virtually debt free, with a Q1 ending cash balance of $9.9 million and outright ownership of two licensed production facilities
Management to Host Conference Call / Webcast on May 13th, 2026, at 10:00 am ET

MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA

Wed, 13 May 2026 07:30:00 -0400

Q1 2026 Positive Adjusted EBITDA(1)
Net Revenue of $9M with strong gross margins of 37%
OPEX decreased 28% in Q1 2026 versus Q4 2025
Company is virtually debt free, with a Q1 ending cash balance of $9.9 million and outright ownership of two licensed production facilities
Management to Host Conference Call / Webcast on May 13th, 2026, at 10:00 am ET

MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA

Wed, 13 May 2026 07:30:00 -0400

Q1 2026 Positive Adjusted EBITDA(1)
Net Revenue of $9M with strong gross margins of 37%
OPEX decreased 28% in Q1 2026 versus Q4 2025
Company is virtually debt free, with a Q1 ending cash balance of $9.9 million and outright ownership of two licensed production facilities
Management to Host Conference Call / Webcast on May 13th, 2026, at 10:00 am ET

MediPharm Labs Positioned to Serve Growing U.S. Pharmaceutical and Clinical Research Demand Following Cannabis Rescheduling

Mon, 27 Apr 2026 08:30:00 -0400

On April 22, 2026, the U.S. Department of Justice and Drug Enforcement Administration’s final order rescheduling FDA-approved cannabis drug products and state-licensed medical cannabis from Schedule I to Schedule III of the Controlled Substances Act took effect.
MediPharm Labs has already supplied product for over 10 active clinical trials, including a U.S. National Institutes of Health funded study, and has completed multiple API and clinical trial material shipments to the United States.
MediPharm Labs is ready today to support expanded U.S. clinical research and pharmaceutical development through its GMP US FDA site registration and Health Canada Drug Establishment License (“DEL”).

TORONTO,